Journal of Clinical Oncology, Vol 19, Issue 8
(April), 2001: 2165-2170
© 2001 American Society for Clinical Oncology
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia
By Susan M. O’Brien,
Hagop Kantarjian,
Deborah A. Thomas,
Francis J. Giles,
Emil J. Freireich,
Jorge Cortes,
Susan Lerner,
Michael J. Keating
From the Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Address reprint requests to: Susan M. O’Brien, MD, Leukemia Department, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030.
PURPOSE: To conduct a dose-escalation trial of rituximab in patients with chronic lymphocytic leukemia (CLL) to define the maximum-tolerated dose (MTD), to evaluate first-dose reactions in patients with high circulating lymphocyte counts, and to assess the efficacy at higher versus lower doses.
PATIENTS AND METHODS: Fifty patients with CLL (n = 40) or other mature B-cell lymphoid leukemias (n = 10) were treated with four weekly infusions of rituximab. The first dose was 375 mg/m2 for all patients; dose- escalation began with dose 2 but was held constant for each patient. Escalated doses were from 500 to 2,250 mg/m2.
RESULTS: Toxicity with the first dose (375 mg/m2) was noted in 94% of patients but was grade 1 or 2 in most, predominantly fever and chills. Six patients (12%) experienced severe toxicity with the first dose, including fever, chills, dyspnea, and hypoxia in all six patients, hypotension in five, and hypertension in one. Toxicity on subsequent doses was minimal until a dose of 2,250 mg/m2 was achieved. Eight (67%) of 12 patients had grade 2 toxicity, including fever, chills, nausea, and malaise, although no patient had grade 3 or 4 toxicity. Severe toxicity with the first dose was significantly more common in patients with other B-cell leukemias, occurring in five (50%) of 10 patients versus one (2%) of 40 patients with CLL (P < .001). The overall response rate was 40%; all responses in patients with CLL were partial remissions. Response rates were 36% in CLL and 60% in other B-cell lymphoid leukemias. Response was correlated with dose: 22% for patients treated at 500 to 825 mg/m2, 43% for those treated at 1,000 to 1,500 mg/m2, and 75% for those treated at the highest dose of 2,250 mg/m2 (P = .007). The median time to disease progression was 8 months. Myelosuppression and infections were uncommon.
CONCLUSION: Rituximab has significant activity in patients with CLL at the higher dose levels. Severe first-dose reactions were uncommon in patients with CLL, even with high circulating lymphocyte counts, but were frequent in patients with other mature B-cell leukemias in which CD20 surface expression is increased. Efficacy of rituximab was also significant in this group of patients.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Hanlon, S. Ellard, C. E. Rudin, S. Thorne, T. Davies, and L. W. Harries
Evaluation of 13q14 Status in Patients with Chronic Lymphocytic Leukemia Using Single Nucleotide Polymorphism-Based Techniques
J. Mol. Diagn.,
July 1, 2009;
11(4):
298 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Pawluczkowycz, F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. J. van de Winkel, P. W. H. I. Parren, and R. P. Taylor
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
J. Immunol.,
July 1, 2009;
183(1):
749 - 758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Foon, M. Boyiadzis, S. R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, et al.
Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
February 1, 2009;
27(4):
498 - 503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Luqman, S. Klabunde, K. Lin, G. V. Georgakis, A. Cherukuri, J. Holash, C. Goldbeck, X. Xu, E. E. Kadel III, S. H. Lee, et al.
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Blood,
August 1, 2008;
112(3):
711 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel
GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment
Cancer Res.,
July 1, 2008;
68(13):
5414 - 5422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Coiffier, S. Lepretre, L. M. Pedersen, O. Gadeberg, H. Fredriksen, M. H. J. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, et al.
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Blood,
February 1, 2008;
111(3):
1094 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda
Treatments for Patients with Chronic Lymphocytic Leukemia
ASCO Educational Book,
January 1, 2008;
2008(1):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, S. O'Brien, I. W. Flinn, T. J. Kipps, M. Weiss, K. Rai, T. S. Lin, J. Woodworth, D. Wynne, J. Reid, et al.
Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
August 1, 2007;
13(15):
4448 - 4455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Williams, J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor
Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia
J. Immunol.,
November 15, 2006;
177(10):
7435 - 7443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. L. Yee and S. M. O'Brien
Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2006;
81(8):
1105 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey and D. M. Goldenberg
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
CA Cancer J Clin,
July 1, 2006;
56(4):
226 - 243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. van Meerten, R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling
Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity.
Clin. Cancer Res.,
July 1, 2006;
12(13):
4027 - 4035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda
Current and Investigational Therapies for Patients with CLL
Hematology,
January 1, 2006;
2006(1):
285 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Abbott
Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment
Oncologist,
January 1, 2006;
11(1):
21 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda, T. J. Kipps, and M. J. Keating
Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
September 10, 2005;
23(26):
6325 - 6332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Lin, M. R. Grever, and J. C. Byrd
Changing the Way We Think About Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
June 20, 2005;
23(18):
4009 - 4012.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, S. O'Brien, M. Albitar, S. Lerner, W. Plunkett, F. Giles, M. Andreeff, J. Cortes, S. Faderl, D. Thomas, et al.
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
June 20, 2005;
23(18):
4079 - 4088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al.
Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
June 1, 2005;
23(16):
3819 - 3829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P Levene, G. Singh, and C. Palmieri
Therapeutic monoclonal antibodies in oncology
J R Soc Med,
April 1, 2005;
98(4):
146 - 152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri, R. M. Saliba, C. Hosing, G.-J. Okoroji, S. Acholonu, P. Anderlini, D. Couriel, M. De Lima, M. L. Donato, L. Fayad, et al.
Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin's Lymphomas
J. Clin. Oncol.,
April 1, 2005;
23(10):
2240 - 2247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Hamaguchi, J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder
The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice
J. Immunol.,
April 1, 2005;
174(7):
4389 - 4399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, et al.
Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma
J. Clin. Oncol.,
February 1, 2005;
23(4):
694 - 704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood,
February 1, 2005;
105(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek and On Behalf Of The German CLL Study Group
Chronic Lymphocytic Leukemia (CLL): First-Line Treatment
Hematology,
January 1, 2005;
2005(1):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Gribben
Salvage Therapy for CLL and the Role of Stem Cell Transplantation
Hematology,
January 1, 2005;
2005(1):
292 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghielmini
Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an Example
Hematology,
January 1, 2005;
2005(1):
321 - 328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, K. Rai, B. L. Peterson, F. R. Appelbaum, V. A. Morrison, J. E. Kolitz, L. Shepherd, J. D. Hines, C. A. Schiffer, and R. A. Larson
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
Blood,
January 1, 2005;
105(1):
49 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Mavragani, P. G. Vlachoyiannopoulos, N. Kosmas, I. Boletis, A. G. Tzioufas, and M. Voulgarelis
A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion
Rheumatology,
November 1, 2004;
43(11):
1450 - 1451.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Enting, A. Demopoulos, L. M. DeAngelis, and L. E. Abrey
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
Neurology,
September 14, 2004;
63(5):
901 - 903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Olszewski and M. L. Grossbard
Empowering Targeted Therapy: Lessons from Rituximab
Sci. Signal.,
July 13, 2004;
2004(241):
pe30 - pe30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghielmini, S.-F. H. Schmitz, S. B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer, M. F. Fey, D. C. Betticher, G. Martinelli, F. Peccatori, et al.
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Blood,
June 15, 2004;
103(12):
4416 - 4423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Bergwelt-Baildon, B. Maecker, J. Schultze, and J. G. Gribben
CD40 activation: potential for specific immunotherapy in B-CLL
Ann. Onc.,
June 1, 2004;
15(6):
853 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Kennedy, P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor
Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia
J. Immunol.,
March 1, 2004;
172(5):
3280 - 3288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Blood,
March 1, 2004;
103(5):
1846 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Farag, I. W. Flinn, R. Modali, T. A. Lehman, D. Young, and J. C. Byrd
Fc{gamma}RIIIa and Fc{gamma}RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
Blood,
February 15, 2004;
103(4):
1472 - 1474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, S. Stilgenbauer, and I. W. Flinn
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2004;
2004(1):
163 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas, S. O'Brien, C. Bueso-Ramos, S. Faderl, M. J. Keating, F. J. Giles, J. Cortes, and H. M. Kantarjian
Rituximab in relapsed or refractory hairy cell leukemia
Blood,
December 1, 2003;
102(12):
3906 - 3911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Castagna, B. Sarina, A. Santoro, J. C. Byrd, K. Rai, and R. A. Larson
Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia
Blood,
September 15, 2003;
102(6):
2309 - 2310.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, D. M. Lucas, A. P. Mone, J. B. Kitner, J. J. Drabick, and M. R. Grever
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis
Blood,
June 1, 2003;
101(11):
4547 - 4550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mangel, R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs, and N. L. Berinstein
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation
Ann. Onc.,
May 1, 2003;
14(5):
758 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, S. Litchy, J. H. Barton, G. A. Houston, R. C. Hermann, J. E. Bradof, and F. A. Greco
Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
J. Clin. Oncol.,
May 1, 2003;
21(9):
1746 - 1751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 1, 2003;
21(9):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, D. A. Thomas, S. O'Brien, G. Garcia-Manero, H. M. Kantarjian, F. J. Giles, C. Koller, A. Ferrajoli, S. Verstovsek, B. Pro, et al.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
Blood,
May 1, 2003;
101(9):
3413 - 3415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bannerji, S. Kitada, I. W. Flinn, M. Pearson, D. Young, J. C. Reed, and J. C. Byrd
Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance
J. Clin. Oncol.,
April 15, 2003;
21(8):
1466 - 1471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Boye, T. Elter, and A. Engert
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Ann. Onc.,
April 1, 2003;
14(4):
520 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Manches, G. Lui, L. Chaperot, R. Gressin, J.-P. Molens, M.-C. Jacob, J.-J. Sotto, D. Leroux, J.-C. Bensa, and J. Plumas
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Blood,
February 1, 2003;
101(3):
949 - 954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps
Biology and Treatment of Chronic Lymphocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
153 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie
Infections in Patients with Hematological Cancer: Recent Developments
Hematology,
January 1, 2003;
2003(1):
438 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
Blood,
January 1, 2003;
101(1):
6 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schulz, S. K. Klein, U. Rehwald, M. Reiser, A. Hinke, W.-U. Knauf, W.-E. Aulitzky, M. Hensel, M. Herold, D. Huhn, et al.
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Blood,
October 16, 2002;
100(9):
3115 - 3120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, S. Litchy, H. A. Burris III, D. C. Scullin Jr, S. W. Corso, D. A. Yardley, L. Morrissey, and F. A. Greco
Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
October 15, 2002;
20(20):
4261 - 4267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. McLaughlin
Progress and Promise in the Treatment of Indolent Lymphomas
Oncologist,
June 1, 2002;
7(3):
217 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, I. Flinn, V. Jain, J.-L. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, et al.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Blood,
May 15, 2002;
99(10):
3554 - 3561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, C. Zervas, A. Zomas, C. Kiamouris, N. A. Viniou, V. Grigoraki, C. Karkantaris, C. Mitsouli, D. Gika, J. Christakis, et al.
Treatment of Waldenstrom's Macroglobulinemia With Rituximab
J. Clin. Oncol.,
May 1, 2002;
20(9):
2327 - 2333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, S. Kitada, I. W. Flinn, J. L. Aron, M. Pearson, D. Lucas, and J. C. Reed
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
Blood,
February 1, 2002;
99(3):
1038 - 1043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay, T. J. Hamblin, D. F. Jelinek, G. W. Dewald, J. C. Byrd, S. Farag, M. Lucas, and T. Lin
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2002;
2002(1):
193 - 213.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I. F. Khouri, R. M. Saliba, S. A. Giralt, M.-S. Lee, G.-J. Okoroji, F. B. Hagemeister, M. Korbling, A. Younes, C. Ippoliti, J. L. Gajewski, et al.
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
Blood,
December 15, 2001;
98(13):
3595 - 3599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson
Some Like It Hot!
J. Clin. Oncol.,
October 1, 2001;
19(19):
3908 - 3911.
[Full Text]
|
|
|
|
|
|
|
K. R. Rai, H. Dohner, M. J. Keating, and E. Montserrat
Chronic Lymphocytic Leukemia: Case-Based Session
Hematology,
January 1, 2001;
2001(1):
140 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
